Mounjaro is tirzepatide; Ozempic is semaglutide. Both are once-weekly injections, both started as diabetes drugs, and both are now famous for weight loss. The difference that matters: Mounjaro hits two gut-hormone receptors (GIP and GLP-1), Ozempic hits one (GLP-1).
When the two molecules were finally tested head-to-head for weight loss, tirzepatide won — about 20% average loss versus roughly 14% for semaglutide. That does not make Ozempic a bad drug; it makes tirzepatide the stronger one on the scale. Here is the full, honest comparison.
The quick answer
If the only question is “which causes more weight loss,” the answer in 2026 is Mounjaro (tirzepatide). The head-to-head SURMOUNT-5 trial settled a debate that had been running on averages from separate studies, and tirzepatide came out clearly ahead. But “which is better for you” is a different question, and it depends on what you are treating, how your body tolerates each one, cost, and what your doctor recommends.
What each one actually is
Start with the branding, because it trips everyone up. Each molecule is sold under two names — one for diabetes, one for obesity:
| Molecule | Diabetes brand | Obesity brand | Receptors |
|---|---|---|---|
| Semaglutide | Ozempic | Wegovy | GLP-1 |
| Tirzepatide | Mounjaro | Zepbound | GIP + GLP-1 |
So “Mounjaro vs Ozempic” is really “tirzepatide vs semaglutide” — the diabetes-branded version of the same rivalry people also call Zepbound vs Wegovy. Ozempic activates the GLP-1 receptor, which curbs appetite and slows stomach emptying. Tirzepatide does that and activates GIP, a second incretin receptor, which appears to add to the effect. For the mechanism in depth, see tirzepatide vs semaglutide.
Ozempic pulls one appetite lever. Mounjaro pulls two. On average, two levers move the scale further — and now there is a head-to-head trial that proves it.Why the dual agonist tends to win
The head-to-head data
For a long time, comparing these two meant lining up results from separate trials — useful, but not proof. That changed with direct comparisons.
For weight loss (SURMOUNT-5): tirzepatide produced about 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks. A clear win for tirzepatide.
For blood sugar (SURPASS-2): in people with type 2 diabetes, tirzepatide also lowered HbA1c more than semaglutide and produced more weight loss, across its dose range.
| Measure | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Avg weight loss (head-to-head, obesity) | ~20.2% | ~13.7% |
| Weight loss (own pivotal trial) | ~20.9% (SURMOUNT-1) | ~14.9% (STEP-1) |
| HbA1c reduction (head-to-head, T2D) | Greater (SURPASS-2) | Strong, but less |
| Receptors | GIP + GLP-1 | GLP-1 |
The direction is consistent across every comparison: tirzepatide edges or beats semaglutide on both weight and blood sugar. Semaglutide remains a highly effective drug with a longer real-world track record — it is simply the runner-up on these specific numbers.
Side effects compared
The side-effect profiles are broadly similar because both work on the same gut-hormone pathways. The headline complaints for both are gastrointestinal: nausea, diarrhoea, constipation, vomiting and reflux, worst during dose escalation and easing over time. Because tirzepatide is often the more potent on weight, some people find its GI effects more noticeable, but head-to-head tolerability has been broadly comparable. Rare but serious risks — pancreatitis, gallbladder problems, and a thyroid-tumour warning carried by the class — apply to both and are part of why they are prescription-only.
Which should you ask about?
There is no universal winner for an individual. Weight loss on the scale favours tirzepatide. But the right choice can come down to which one your body tolerates, which is covered or affordable for you, which your doctor has experience prescribing, and whether you are treating diabetes, obesity, or both. Some people do very well on semaglutide and never need to switch.
Both are prescription medicines. This comparison is background for a conversation with your doctor, not a recommendation or dosing guidance. The choice between them should be made with a clinician who knows your history.
The research-peptide angle
Both molecules also exist in the research-peptide market, which is where a supplier like TrueLabs comes in. Semaglutide and tirzepatide are sold as raw compounds for laboratory study — tirzepatide is listed here as TZ-2. The important distinction is the same one that applies to any of these drugs: a research compound is not the prescription medicine. It is an unapproved raw material for in vitro work, without the sterile formulation, verified dose or clinical oversight of Mounjaro or Ozempic. Anyone comparing the two for actual use is comparing medicines, and that belongs with a doctor, not a peptide catalogue. For context on sourcing and quality, see how to spot fake peptides.
Mounjaro vs Ozempic myths
“Myth: Ozempic and Mounjaro are basically the same drug.”
They are different molecules. Ozempic is semaglutide (one receptor); Mounjaro is tirzepatide (two receptors). That difference shows up in the results.
“Myth: Mounjaro is always the better choice.”
It wins on average weight loss, but the best drug for a given person depends on tolerance, cost, coverage and what is being treated. Many people do very well on semaglutide.
“Myth: Ozempic is for weight loss.”
Ozempic is approved for type 2 diabetes. The weight-management brand of semaglutide is Wegovy. Prescribing Ozempic for weight loss is off-label.
“Myth: You can swap between them freely.”
Switching is a medical decision with its own dose considerations. It is not a casual trade, and it should be managed by a clinician.
For researchers
TrueLabs supplies tirzepatide as TZ-2 from $73, retatrutide as RT3 from $90, and Cagrilintide from $40 — the incretin and amylin compounds behind this entire category — in CAD for in vitro and laboratory research only. Before ordering, see how to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
Is Mounjaro better than Ozempic for weight loss?
On average, yes. The head-to-head SURMOUNT-5 trial reported about 20.2% weight loss for tirzepatide (Mounjaro/Zepbound) versus 13.7% for semaglutide (Ozempic/Wegovy) over 72 weeks.
What is the difference between Mounjaro and Ozempic?
Mounjaro is tirzepatide, which activates two gut-hormone receptors (GIP and GLP-1). Ozempic is semaglutide, which activates one (GLP-1). Both are once-weekly injections.
Are Mounjaro and Ozempic the same drug?
No. They are different molecules from different manufacturers. They work on overlapping pathways, which is why they are often compared.
Which has worse side effects?
Both cause mainly gastrointestinal side effects, and head-to-head tolerability has been broadly similar. Because tirzepatide is often more potent, some people notice its effects more, but there is no large gap.
Is Ozempic or Mounjaro approved for weight loss?
The weight-management brands are Wegovy (semaglutide) and Zepbound (tirzepatide). Ozempic and Mounjaro are approved for type 2 diabetes; using them for weight loss is off-label.
Can I switch from Ozempic to Mounjaro?
Possibly, but it is a medical decision with its own dose considerations and should be managed by your doctor, not done on your own.
Which is cheaper in Canada?
Prices and coverage vary, and weight-loss use is often not covered by public plans. Cost should be checked for your specific situation and pharmacy.
Is research tirzepatide the same as Mounjaro?
No. Research tirzepatide (such as TrueLabs TZ-2) is a raw compound for laboratory use, not the regulated, dose-formulated medicine. The molecule may match, but the status and oversight do not.
Related reading
- Tirzepatide vs semaglutide
- Zepbound in Canada
- Retatrutide vs tirzepatide vs semaglutide
- Generic Ozempic in Canada
- Weight-loss injections in Canada
References
- Aronne LJ, et al. Tirzepatide versus Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. NEJM
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. NEJM
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. NEJM
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384:989-1002. NEJM
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.